-
Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra in Patients With Revlimid Refractory or Resistant Deletion 5q Myelodysplastic Syndrome
Tuesday, June 7, 2011 - 4:06pm | 128Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome. This is a multicenter trial intended to enroll up to 117 evaluable patients. It employs a...
-
Top Percentage Gainers and Losers as of 2pm 06/07/11
Tuesday, June 7, 2011 - 2:27pm | 642Best 1) Temple-Inland (NYSE: TIN): Trading up 41.3% from yesterday's close to $29.67. International Paper put in a bid to acquire Temple-Inland for $30.60 per share. Temple's board rejected the deal, saying that the bid undervalued the company. 2) Westinghouse Solar (NASDAQ: WEST): Trading up 28...
-
Biotech Q&A; BioSante Announces Completion of Enrollment in LibiGel Safety Study
Tuesday, June 7, 2011 - 1:45pm | 1361Point Roberts, WA, LINCOLNSHIRE, Ill - June 7, 2011 - (Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, features an exclusive Q&A interview and update with Mr. Stephen M. Simes, president and chief...
-
Acorda Therapeutics Jumping On Takeover Rumors
Tuesday, June 7, 2011 - 1:38pm | 58Acorda Therapeutics Inc. (NASDAQ: ACOR) shares are jumping after news hit the wires that Biogen Idec (NASDAQ: BIIB) may be looking for a partner in multiple sclerosis drugs. At last check, shares of Acorda Therapeutics were up $1.06 to $31.94, a gain of around 3%.
-
Top Percentage Gainers and Losers as of 12pm 06/07/11
Tuesday, June 7, 2011 - 12:00pm | 515Best 1) Temple-Inland (NYSE: TIN): Trading up 39.8% from yesterday's close to $29.37. International Paper (NYSE: IP) put in a bid to acquire Temple-Inland for $30.60 per share. Temple's board rejected the deal, saying that the bid undervalued the company. 2) Westinghouse Solar (NASDAQ: WEST):...
-
EntreMed Announces Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China
Tuesday, June 7, 2011 - 11:50am | 60EntreMed, Inc. (Nasdaq: ENMD) today announced that Selected Value Therapeutics I, LLC has exercised its right to acquire an exclusive license to develop and commercialize EntreMed's Phase 2 oncology drug candidate, ENMD-2076, in China and certain of its territories. EntreMed retains development...
-
Immunomedics Reports Final Survival Data With Yttrium-90-Labeled Clivatuzumab Tetraxetan and Low-Dose Gemcitabine in Advanced Pancreatic Cancer
Tuesday, June 7, 2011 - 11:35am | 86Immunomedics, Inc. (Nasdaq: IMMU) today announced that treatment with its proprietary humanized antibody, clivatuzumab tetraxetan, labeled with yttrium-90 and combined with low-dose gemcitabine, demonstrated promising therapeutic activity in patients with advanced, inoperable, pancreatic cancer....
-
OPKO Health Announces Research Grants from Mexican Technology and Science Council
Tuesday, June 7, 2011 - 9:42am | 65OPKO Health (NYSE: OPK) today announced the award of research grants in 2011 totaling more than US$1 million from the Mexican national technology and science council (Consejo Nacional de Ciencia y Tecnología, CONACYT). The grants will be used by Exakta-OPKO, OPKO's wholly-owned Mexican subsidiary,...
-
Neuralstem and Summit Pharmaceuticals Enter Into Exclusive Agency Agreement to License NSI-189 Rights in Japan
Tuesday, June 7, 2011 - 9:42am | 64Neuralstem, Inc. (NYSE: CUR) announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan, a wholly owned subsidiary of Sumitomo Corporation Group. Under the agreement, SPI will market development and licensing rights...
-
Cephalon Presents Encouraging Results of Obatoclax, in Extensive-Stage Small Cell Lung Cancer at ASCO Annual Meeting
Tuesday, June 7, 2011 - 9:40am | 351Today, Cephalon (NASDAQ: CEPH) presented new phase 2 data on an investigational compound, obatoclax, at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill. The data show that patients with extensive-stage small cell lung cancer receiving obatoclax in addition to...
-
Auriga Comments On United Therapeutics Top-Line Results
Tuesday, June 7, 2011 - 8:50am | 101According to Auriga, United Therapeutics (NASDAQ: UTHR) reported preliminary top-line results from the closely watched FREEDOM-M trial. Auriga said that the primary endpoint was change in 6 Minute Walk Distance (6MWD) at 12 weeks for 228 patients that received 0.25 mg dose increments. “Results...
-
Jefferies & Company Reports on Incyte
Tuesday, June 7, 2011 - 8:24am | 151Jefferies & Company commented on Incyte (NASDAQ: INCY) in a report released yesterday. In the report, Jefferies & Company was positive in its assessment of the company. Jefferies & Company writes, "INCY released new detail from the COMFORT-2 European study of ruxolitinib in...
-
Jefferies Provides Color on Ariad Pharmaceuticals, Buy
Tuesday, June 7, 2011 - 8:17am | 102Jefferies provided color on Ariad Pharmaceuticals (NASDAQ: ARIA). In a research report published today, Jefferies commented on the company's ridaforolimus drug testing process. In the report, Jefferies states, "ARIA presented updated ridaforolimus OS data yesterday at ASCO in bone and soft tissue...
-
Brean Murray Carret Increases Price Target On Incyte To $25
Tuesday, June 7, 2011 - 8:14am | 50According to Brean Murray Carret, Incyte (NASDAQ: INCY) price target is increased to $25 from $23. Brean Murray Carret said that, due to the solid Phase 3 details and clarity of the anemia effect, it is increasing the target price to $25. Incyte closed yesterday at $16.90.
-
Benzinga's Top Downgrades
Tuesday, June 7, 2011 - 8:14am | 140Analysts at JP Morgan downgraded Citrix Systems Inc (NASDAQ: CTXS) from “neutral” to “underweight.” CTXS's shares closed at $82.15 yesterday. Citrix Systems' PEG ratio is 2.54. Analysts at Citadel Securities downgraded United Therapeutics Corporation (NASDAQ: UTHR) from “add” to “neutral.” UTHR's...